Several phase II clinical trials involved targeting Her2 prostate cancers by infusing trastuzumab (Herceptin) into prostate cancer patients; however, one study closed due to inability to accrue sufficient numbers of HER2+ patients [8] and another study failed to demonstrate benefit in CRPC patients [9]. Here, ERBB2 is linked to Familial prostate cancer.